1. Genetic variability of pain perception and treatment—clinical pharmacological implications

   • Jörn Lötsch

   Review Article 23 February 2011 Pages: 541 - 551

2. Combination therapy with diltiazem plus CsA/MMF/Pred or CsA/Aza/Pred triple immunosuppressive regimens for use in clinical kidney transplantation in Northwestern China

   • Yong Song
   • Wujun Xue
   • Xiaohu Fan

   Clinical Trial 29 January 2011 Pages: 553 - 562

   

3. Early phase drugs and biologicals clinical trials on worldwide leading causes of death: a descriptive analysis

   • Rafael Dal-Ré

   Special Article 05 April 2011 Pages: 563 - 571

4. The influence of tocolytic drugs on cardiac function, large arteries, and resistance vessels

   • Isabelle G. Fabry
   • Peter De Paepe
   • Luc M. Van Bortel

   Pharmacodynamics 15 April 2011 Pages: 573 - 580

5. The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement

   • Shi-Long Zhong
   • Yuan Liu
   • Shu-Guang Lin

   Pharmacogenetics 12 February 2011 Pages: 581 - 590

   

6. Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C

   • Samir K. Gupta
   • Karen Kolz
   • David L. Cutler

   Pharmacokinetics and Disposition 16 December 2010 Pages: 591 - 599

   

7. Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients

   • Bing Chen
   • WeiXia Zhang
   • WeiMin Cai

   Pharmacokinetics and Disposition 16 December 2010 Pages: 601 - 612

   

8. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials

   • Xiao Feng Hang
   • Wen Sheng Xu
   • Wu Ni

   Pharmacoepidemiology and Prescription 18 January 2011 Pages: 613 - 623

   

9. Adverse drug events in an intensive care unit of a university hospital

   • Adriano Max Moreira Reis
   • Silvia Helena De Bortoli Cassiani

   Pharmacoepidemiology and Prescription 19 January 2011 Pages: 625 - 632

10. Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database

    • Johanna Strandell
    • Stina Wahlin

    Pharmacoepidemiology and Prescription 21 January 2011 Pages: 633 - 641

11. Erratum to: Are results from pharmaceutical-company-sponsored studies available to the public?

    • Rafael Dal-Ré
    • Alejandro Pedromingo
    • Rafael Ortega

    Erratum 12 April 2011 Pages: 643 - 643

12. Author’s response to the Letter to the Editor of Tfelt-Hansen

    • Ana Macedo
    • Magí Farré
    • Josep-E. Baños

    Letter to the Editors 21 November 2010 Pages: 645 - 646

13. Placebo response in migraine

    • Peer Tfelt-Hansen

    Letter to the Editors 23 November 2010 Pages: 647 - 647

14. Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009–2010 mass vaccination campaign in France

    • Céline Caillet
    • Genevieve Durrieu
    • The French Network of Pharmacovigilance Centres

    Letter to the Editors 14 December 2010 Pages: 649 - 651